Image: Richard Nyberg, USAID

The Fleming Fund is a UK Government aid programme to help low and middle income countries address priorities in tackling antimicrobial resistance (AMR), through a diverse range of projects.

The aim of the Fleming Fund is to support countries in collecting relevant high quality data that is shared nationally and globally. This will enable us collectively to better understand the scale and scope of the problem in order to effectively tackle the issue.


What will the Fleming Fund focus on?

  • Supporting the development of National Action Plans for AMR.
  • Developing and supporting the implementation of protocols and guidance for AMR surveillance and antimicrobial use.
  • Building laboratory capacity for diagnosis.
  • Collecting drug resistance data.
  • Enabling the sharing of drug resistance data locally, regionally, and internationally.
  • Collating and analysing data on the sale and use of antimicrobial medicines.
  • Advocating for the application of data to promote the rational use of antimicrobials.
  • Shaping a sustainable system for AMR surveillance and data sharing.
  • Supporting fellowships to provide strong national leadership in addressing AMR.


Why focus on AMR surveillance?

Countries need robust surveillance data on AMR and the use of antimicrobials in order to make informed decisions on their priorities and allocate (often scarce) resources to tackle AMR. Good quality surveillance data is therefore key to delivering effective national responses to AMR.

International strategies on AMR have recommended improving surveillance as a key intervention to tackling the problem. These include the Lord O'Neil AMR Review comissioned by the UK government, the Global Action Plan on AMR published by the WHO and the Interagency Coordination Group Framework for Action on AMR. The Fleming Fund and its objectives represents an important part of the UK's contribution to fulfilling recommendations detailed in these plans.


What does success look like and how will it be measured?

By 2022, the Fleming Fund will have helped 24 low and middle income countries to establish sustainable surveillance programmes for antimicrobial resistance and for monitoring of antimicrobial use in human and animal health. Outcomes will be an increase in relevant high quality data that are shared nationally and globally, and that form the basis for changes in policy and practice that advocate the rationale use of antimicrobial medicines.


Where will the Fund operate?

The regional focus of the programme is in Sub-Saharan Africa, South and South-East Asia with country grants expected in 24 initial priority countries, identified through a detailed review and key informant interviews.


Who is delivering the Fleming Fund?

The Fleming Fund is led by the UK Department of Health and Social Care (DHSC) and delivered through a number of key partners.


When will the Fleming Fund be active at a country level?

Many countries are already working with the Fleming Fund to pilot surveillance protocols, to report data on the use of antibiotics in animals, to develop AMR national action plans and a number of other key activities. The Fleming Fund country grants programme has been in designed with support from other partners and has begun to reach out to countries on a rolling basis. The country grants scheme is currently actively engaging in Vietnam, Uganda, Ghana and Burma. Click here for more information.